Kentucky reaches OxyContin, Risperdal settlements; Valeant's Walgreens pact won't solve its growth problems;

> Kentucky has reached two separate settlements totaling $39.5 million--one each with Purdue and Johnson & Johnson ($JNJ) over their respective meds, OxyContin and Risperdal. More

> Valeant's ($VRX) new pricing and distribution pact with Walgreens ($WBA) likely won't bring the company the same revenue growth it generated with high-priced branded drugs, doctors and investors say. More

> India has added drugs for cancer, HIV/AIDS and hepatitis C to its essential medicines list in hopes of making them more affordable. More

> The New England Journal of Medicine has published positive results of two trials of Novartis' ($NVS) Cosentyx in ankylosing spondylitis. Release

And Finally... The U.S. Drug Enforcement Agency (DEA) is easing the regulatory requirements that were previously imposed on those conducting FDA-approved clinical trials on cannabidiol. More

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.